Bessemer Group
CAPR icon

Bessemer Group’s Capricor Therapeutics CAPR Stock Holding History

Bessemer Group’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-26
Closed – – 2503
2025
Q2 		$0 Hold
26
– – ﹤0.01% 2413
2025
Q1 		$0 Buy
+26
New +$361 ﹤0.01% 2467

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bessemer Group's CAPR Position: Q3 2025 in Review

Bessemer Group sold out of Capricor Therapeutics (CAPR) in Q3 2025, closing a stake of 26 shares.

Bessemer Group first reported a position in CAPR in Q1 2025 and held it in 2 quarters. The position peaked at $0 in Q2 2025. 115 funds tracked by Wall St. Rank hold CAPR as of Q3 2025.

  • Bessemer Group reported no remaining Capricor Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bessemer Group sold 26 Capricor Therapeutics shares in Q3 2025.
  • Bessemer Group first reported a position in Capricor Therapeutics in Q1 2025 and held it in 2 quarters.
  • Bessemer Group's Capricor Therapeutics position peaked at $0 in Q2 2025.
  • 115 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2025.

Based on Bessemer Group's 13F filing for Q3 2025, filed 5 Nov 2025.